For laboratory research only. Not for human consumption.Our comparison method ↗
Studio-style Deals on Peptides product visual for SS-31

Vial comparison

SS-31 prices

Compare SS-31 listings by strength, selection and supplier. Inspect the original source behind each price.

27suppliers represented
45source-linked listings
7strengths available

MATCH SIZE AND QUANTITY

Build your comparison.

Daily snapshot · inspect sources

Choose a labeled amount and selection to load matching prices.

GO BEYOND THE PRICE

Track it. Plan it. Inspect it.

Select a strength and selection above to view price history, save a price watch or add it to your basket.

DOCUMENTATION PASSPORTS

Reports and batch records

Search all batch records

Inspect the source report, recorded lot and document access. A report link does not confirm the batch currently shipping.

Loading documentation records…

Listed amounts and selections

  • 10 mg18 suppliers · Pack counts: 1, 3, 5, 10
  • 25 mg1 supplier · Pack counts: 1
  • 30 mg1 supplier · Pack counts: 1
  • 35 mg1 supplier · Pack counts: 1
  • 50 mg13 suppliers · Pack counts: 1, 3, 5, 10
  • 57 mg1 supplier · Pack counts: 1
  • 60 mg1 supplier · Pack counts: 1

Reported quantities in this family: 1, 3, 5, 10. Counts and units must be matched to the exact listing.

Compare the exact selection

Choose the labeled amount per unit and quantity before comparing. A single unit and a multipack have different upfront prices. Keep product format and exact recipe consistent; similar names do not establish equivalent products.

Follow the original listing to check its quantity, availability and current price. Unit prices use the full labeled mass in each selection.

Single-vial price overview

Compare within each strength. Every row covers one vial and includes only listings marked in stock with known quantities.

Listed total prices before additional promotions or coupon estimates. Includes supplier captures and aggregator reports; capture dates do not confirm current vendor price or stock. Shipping and tax extra. Open the source before relying on a price.
StrengthSelectionLowest listed total pricePrice per mgSupplier countCompare
10 mg1 vial$26.94$2.6917Compare
25 mg1 vial$139.99$5.601Compare
30 mg1 vial$74.95$2.501Compare
50 mg1 vial$79.00$1.5810Compare
57 mg1 vial$76.99$1.351Compare
60 mg1 vial$179.99$3.001Compare

Suppliers with SS-31 listings

27 profiles
View 21 more supplier profiles

Sources and comparison limits

4 listings from direct supplier captures and 41 listings from aggregator reports. Capture and import dates record when data was obtained; they do not guarantee the supplier’s current price or stock.

Listings include out-of-stock and unconfirmed-stock records. Inclusion does not certify a supplier, a batch or a product. Read how matching and source dates work.

Explore more vial listings

Browse all products

FROM PEPTIDES CALCULATOR

About SS-31

Source profile reviewed 2026-10-01 · Imported 2026-10-22. Read the full compound profile

SS-31, known generically as elamipretide and by the development codes MTP-131 and Bendavia, is a synthetic four-residue peptide designed by Hazel Szeto and Peter Schiller that concentrates in the inner mitochondrial membrane and binds the phospholipid cardiolipin. Stealth BioTherapeutics took it through trials in primary mitochondrial myopathy, heart failure, reperfusion injury, dry age-related macular degeneration and Barth syndrome, and the large trials in mitochondrial myopathy and macular degeneration both missed their primary endpoints. On September 19, 2025 the FDA granted accelerated approval to Forzinity (elamipretide) injection, 40 mg subcutaneously once daily, to improve muscle strength in people with Barth syndrome weighing at least 30 kg, based on knee extensor strength in a 12-patient trial, with a confirmatory trial required. Powder sold online as SS-31 is a research chemical rather than the approved product, and community guides describe it at a fraction of the labeled dose.

Formula
C32 H49 N9 O5
Molar mass
639.8 g/mol
CAS number
736992-21-5
Amino acids
4

Research evidence described in the source

Human

Negative MMPOWER-3 primary endpoints

In 218 participants, 40 mg/day did not significantly improve six-minute walk distance or fatigue overall.

Human

Earlier dose-escalation trial

A short phase 1/2 study evaluated IV doses and exercise outcomes.

Review

Post-hoc subgroup caution

Signals in genotype subgroups require prospective confirmation and do not overturn the overall result.

Limitations noted in the source

  • The 40 mg/day trial dose and investigational formulation differ from small-vial presets.
  • Post-hoc responder analyses are hypothesis-generating.
  • A calculator preset is a recorded research convention, not a recommendation or evidence of clinical benefit.
  • Identity, purity, sterility, and stability can vary substantially outside regulated manufacturing.
Publications and references linked by the source

Background is reproduced from Peptides Calculator with attribution. The source describes compound-level research. It does not evaluate the identity, quality or suitability of a listed supplier’s product or batch.